MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

PHR.US

9.06

+0.33%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.61 0.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.55

Max

1.6400000000000001

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+140.88% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	22M 674M
Eelmine avamishind	0.99
Eelmine sulgemishind	1.61

Uudiste sentiment

By Acuity

50%

151 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2026, 17:26 UTC

Uudisväärsed sündmused

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. apr 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Market Talk Roundup: Latest on U.S. Politics

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. apr 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:15 UTC

Market Talk

Uudisväärsed sündmused

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. apr 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. apr 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. apr 2026, 23:01 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. apr 2026, 22:58 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

7. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. apr 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. apr 2026, 19:17 UTC

Uudisväärsed sündmused

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. apr 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. apr 2026, 18:41 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. apr 2026, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. apr 2026, 18:39 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. apr 2026, 18:24 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. apr 2026, 16:21 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

140.88% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 140.88%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

151 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.